Healthcare [ 12/13 ] | Biotechnology [ 116/164 ]
NASDAQ | Common Stock
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases.
It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.
The company is headquartered in New York, New York.
Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 12, 24 | -0.36 Increased by +26.53% | -0.43 Increased by +16.28% |
| Nov 9, 23 | -0.45 Decreased by -9.76% | -0.47 Increased by +4.26% |
| Aug 10, 23 | -0.57 Decreased by -62.86% | -0.45 Decreased by -26.67% |
| May 22, 23 | -0.46 Decreased by -12.20% | -0.43 Decreased by -6.98% |
| Feb 3, 23 | -0.49 Decreased by -36.11% | -0.39 Decreased by -25.64% |
| Nov 4, 22 | -0.41 Decreased by -17.14% | -0.39 Decreased by -5.13% |
| Aug 5, 22 | -0.35 Decreased by -12.90% | -0.40 Increased by +12.50% |
| Jun 8, 22 | -0.41 Decreased by -41.38% | -0.38 Decreased by -7.89% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 23 | 0.00 Decreased by N/A% | -51.42 M Increased by +18.68% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -58.66 M Decreased by -22.40% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -73.94 M Decreased by -83.13% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -59.43 M Decreased by -25.99% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -63.23 M Decreased by -52.78% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -47.93 M Decreased by -27.12% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -40.37 M Decreased by -32.50% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -47.17 M Decreased by -67.52% | Decreased by N/A% Decreased by N/A% |